New research suggests that people who stop using new GLP-1 drugs like Mounjaro or Wegovy may regain shed pounds much more quickly than those who end traditional diet and exercise regimens.
Published data in a leading health publication shows that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an estimated rate of nearly a kilo each month once they quit.
"Users using these treatments should be informed of the risk of quick rebound weight gain when the treatment ends," stated researcher Dr. Susan Jebb.
Such speed of recovery implies a return to original weight in about 18 months.
Weighing Therapies
The research, which reviewed dozens of studies involving over 9,000 of participants, contrasted the results of the injectable medications with other pills.
Researchers note that individuals who lose weight through diet and exercise typically have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Rapid Rebound
Experts believe the way of the injections is key to understanding the heightened weight return.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls hunger.
"Sustained high doses of GLP-1 concentrations far above than normal might result in the system to generate a reduced amount of its endogenous GLP-1, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement results in appetite is unsuppressed, making binge eating much more probable."
A Lifelong Condition?
Health authorities recommend the injections for people with obesity-related health risks, accompanied by prescribed diet and exercise modifications.
A number of clinicians contend that, due to the likelihood of weight regain, the treatment might need to be long-term.
This perspective is supported by pharmaceutical companies, who state that the findings "underscore the persistent nature of obesity," similar to managing diseases like high blood pressure.
User Experiences
Individuals who have discontinued the jabs explain a intense return of hunger.
"It felt as if a trigger that goes on and I was suddenly ravenous," described one woman.
This difficulty is worsened if patients have not developed sustainable lifestyle or habit changes during treatment.
Widespread Use
Recent estimates show that millions of adults in the UK have used these injections in the past year, with desire remaining high.
- Use is higher among females than men.
- The middle-aged demographic shows the highest level of interest.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
In conclusion, researchers emphasize that while the jabs are powerful agents for shedding pounds, they are not a standalone solution and lasting health benefits relies on ongoing behavioural support.
